Copyright Reports & Markets. All rights reserved.

Global Myocardial Infarction Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Myocardial Infarction Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Myocardial Infarction Treatment Market Size Growth Rate by Product
      • 1.4.2 Antiplatelet Agents
      • 1.4.3 Glycoprotein IIb/IIIa Inhibitors
      • 1.4.4 Antithrombotic Agents
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Myocardial Infarction Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Myocardial Infarction Treatment Market Size
      • 2.1.1 Global Myocardial Infarction Treatment Revenue 2014-2025
      • 2.1.2 Global Myocardial Infarction Treatment Sales 2014-2025
    • 2.2 Myocardial Infarction Treatment Growth Rate by Regions
      • 2.2.1 Global Myocardial Infarction Treatment Sales by Regions
      • 2.2.2 Global Myocardial Infarction Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Myocardial Infarction Treatment Sales by Manufacturers
      • 3.1.1 Myocardial Infarction Treatment Sales by Manufacturers
      • 3.1.2 Myocardial Infarction Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Myocardial Infarction Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Myocardial Infarction Treatment Revenue by Manufacturers
      • 3.2.1 Myocardial Infarction Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Myocardial Infarction Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Myocardial Infarction Treatment Price by Manufacturers
    • 3.4 Myocardial Infarction Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Myocardial Infarction Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Myocardial Infarction Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Myocardial Infarction Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Myocardial Infarction Treatment Sales by Product
    • 4.2 Global Myocardial Infarction Treatment Revenue by Product
    • 4.3 Myocardial Infarction Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Myocardial Infarction Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Myocardial Infarction Treatment by Countries
      • 6.1.1 North America Myocardial Infarction Treatment Sales by Countries
      • 6.1.2 North America Myocardial Infarction Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Myocardial Infarction Treatment by Product
    • 6.3 North America Myocardial Infarction Treatment by End User

    7 Europe

    • 7.1 Europe Myocardial Infarction Treatment by Countries
      • 7.1.1 Europe Myocardial Infarction Treatment Sales by Countries
      • 7.1.2 Europe Myocardial Infarction Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Myocardial Infarction Treatment by Product
    • 7.3 Europe Myocardial Infarction Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Myocardial Infarction Treatment by Countries
      • 8.1.1 Asia Pacific Myocardial Infarction Treatment Sales by Countries
      • 8.1.2 Asia Pacific Myocardial Infarction Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Myocardial Infarction Treatment by Product
    • 8.3 Asia Pacific Myocardial Infarction Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Myocardial Infarction Treatment by Countries
      • 9.1.1 Central & South America Myocardial Infarction Treatment Sales by Countries
      • 9.1.2 Central & South America Myocardial Infarction Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Myocardial Infarction Treatment by Product
    • 9.3 Central & South America Myocardial Infarction Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Myocardial Infarction Treatment by Countries
      • 10.1.1 Middle East and Africa Myocardial Infarction Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Myocardial Infarction Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Myocardial Infarction Treatment by Product
    • 10.3 Middle East and Africa Myocardial Infarction Treatment by End User

    11 Company Profiles

    • 11.1 Bayer
      • 11.1.1 Bayer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Bayer Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Bayer Myocardial Infarction Treatment Products Offered
      • 11.1.5 Bayer Recent Development
    • 11.2 Novartis
      • 11.2.1 Novartis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Novartis Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Novartis Myocardial Infarction Treatment Products Offered
      • 11.2.5 Novartis Recent Development
    • 11.3 Daiichi Sankyo
      • 11.3.1 Daiichi Sankyo Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Daiichi Sankyo Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Daiichi Sankyo Myocardial Infarction Treatment Products Offered
      • 11.3.5 Daiichi Sankyo Recent Development
    • 11.4 Boehringer Ingelheim
      • 11.4.1 Boehringer Ingelheim Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Boehringer Ingelheim Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Boehringer Ingelheim Myocardial Infarction Treatment Products Offered
      • 11.4.5 Boehringer Ingelheim Recent Development
    • 11.5 Astrazeneca
      • 11.5.1 Astrazeneca Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Astrazeneca Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Astrazeneca Myocardial Infarction Treatment Products Offered
      • 11.5.5 Astrazeneca Recent Development
    • 11.6 Janssen Biotech
      • 11.6.1 Janssen Biotech Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Janssen Biotech Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Janssen Biotech Myocardial Infarction Treatment Products Offered
      • 11.6.5 Janssen Biotech Recent Development
    • 11.7 Merck
      • 11.7.1 Merck Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Merck Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Merck Myocardial Infarction Treatment Products Offered
      • 11.7.5 Merck Recent Development
    • 11.8 Sanofi
      • 11.8.1 Sanofi Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Sanofi Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Sanofi Myocardial Infarction Treatment Products Offered
      • 11.8.5 Sanofi Recent Development
    • 11.9 Pfizer
      • 11.9.1 Pfizer Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Pfizer Myocardial Infarction Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Pfizer Myocardial Infarction Treatment Products Offered
      • 11.9.5 Pfizer Recent Development

    12 Future Forecast

    • 12.1 Myocardial Infarction Treatment Market Forecast by Regions
      • 12.1.1 Global Myocardial Infarction Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Myocardial Infarction Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Myocardial Infarction Treatment Market Forecast by Product
      • 12.2.1 Global Myocardial Infarction Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Myocardial Infarction Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Myocardial Infarction Treatment Market Forecast by End User
    • 12.4 North America Myocardial Infarction Treatment Forecast
    • 12.5 Europe Myocardial Infarction Treatment Forecast
    • 12.6 Asia Pacific Myocardial Infarction Treatment Forecast
    • 12.7 Central & South America Myocardial Infarction Treatment Forecast
    • 12.8 Middle East and Africa Myocardial Infarction Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Myocardial Infarction Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
      The global Myocardial Infarction Treatment market is valued at 1360 million US$ in 2018 and will reach 2180 million US$ by the end of 2025, growing at a CAGR of 6.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Myocardial Infarction Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Myocardial Infarction Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Myocardial Infarction Treatment in these regions.
      This research report categorizes the global Myocardial Infarction Treatment market by top players/brands, region, type and end user. This report also studies the global Myocardial Infarction Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Bayer
      Novartis
      Daiichi Sankyo
      Boehringer Ingelheim
      Astrazeneca
      Janssen Biotech
      Merck
      Sanofi
      Pfizer

      Market size by Product
      Antiplatelet Agents
      Glycoprotein IIb/IIIa Inhibitors
      Antithrombotic Agents
      Others
      Market size by End User
      Hospital
      Clinic

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Myocardial Infarction Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Myocardial Infarction Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Myocardial Infarction Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Myocardial Infarction Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Myocardial Infarction Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Myocardial Infarction Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now